SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 7/25/2017 8:44:53 PM - Followers: 37 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

Company Description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001 has completed a combination (with LDAC) safety phase  8 cohort for treatment of AML. No toxicity was seen. 5 out of 6 patients acheived at least partial remission. 50% had total remission! The company has completed the review by the FDA for this drug and begun phase II. The patient dosing has begun at trials which will occur at up to 10 sites or more, including MD Anderson, Weill Cornell Medical College Presbyterian Hospital,
Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug is BP1001 targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the 8 cohort of phase 1 (treating different types of leukemia) there has been absolutely no toxicity. Testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating our delivery system. The combination safety trials with LDAC are complete. Phase 2 has begun and is accepting patients. This trial will occur at several sites. The purpose of phase 2 will be to test the effectiveness of the drug. The company may explore FDA accelerated status after testing is complete on 19 additional patients which is expected to occur in the 3rd quarter of 2017. A CML combination drug safety study for BP1001 is also expected to be completed by mid to late 2017. Patent protection for their neutral lipid delivery system has been allowed.
 
Bio-Path Holdings will also begin phase 1 testing of their antisense drug BP1001 on certain types of breast cancer which the date have been resistant to treatment.  Additionally, BPTH is initiating development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected for early 2017.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there is now renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. If Bio-Path holdings proves the validity of their delivery system, I would expect similar partnerships.

This link to the company website describes their novel delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson was the largest shareholder. After raising an additional funds  the company has 9+ million in cash. These funds should allow the company to start phase II testing of their antisense drug BP1001 on leukemia and begin phase I testing for breast cancer. The company has an "at the market" credit facility in place with Cantor Fitzgerald to raise another $25 million.

 
Bio-Path Holdings do not manufacture their drug but uses contractors. Once the efficacy of BP1001 is established, I would anticipate a manufacturing partnership will occur. The CEO says the company has now ramped up their structure as they are a phase 2 developmental company.
 
BPTH is traded on the NASDAQ.

Here is the link to the peer paper prepared by their experts:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/pdf/PeerExpertOpinion20150107.pdf

Analyst target price: Maxim $2, Rodman & Renshaw $5, HC Wainwright a buy with a $5.00 target, Stonegate Capital Blackstone $4. Thompson Reuters rates BPTH as out perform with a target of $3.25. MSCI raised BPTH from 1 to 3.


Zack's rating now equals hold.

                        
 
 
 
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#2857   moffat, I do not the answer to your SJSTOCKSHARK 07/25/17 08:44:53 PM
#2856   They have stated the delivery system is ready dmoffat 07/25/17 10:38:44 AM
#2855   Pstates, Are we talking about BP-1001 or the SJSTOCKSHARK 07/25/17 10:14:19 AM
#2854   Hi again everyone. I agree with dmoffat in PStates 07/25/17 12:11:44 AM
#2853   Then PN needs to step up and get dmoffat 07/24/17 06:16:39 PM
#2852   Moffat, Until BPTH clears up the delisting issue SJSTOCKSHARK 07/24/17 03:08:56 PM
#2851   Especially since a couple brokers have come out dmoffat 07/24/17 01:10:29 PM
#2850   That seems like an awful high risk to dmoffat 07/24/17 12:53:17 PM
#2849   Moffat, Others who would short the stock are SJSTOCKSHARK 07/24/17 12:50:02 PM
#2848   That leads me to believe they are raising dmoffat 07/24/17 11:24:06 AM
#2847   The shorts are hammering the ask again. It SJSTOCKSHARK 07/24/17 11:02:53 AM
#2846   Gp, I have Stonegate listed in the Ibox SJSTOCKSHARK 07/24/17 10:43:34 AM
#2845   I just happened on a press release dated Gpheart2016 07/24/17 10:00:49 AM
#2844   Pat, Hopefully by 8/15/17 we will receive an SJSTOCKSHARK 07/21/17 01:38:04 PM
#2843   I think you're right that if the fee Pat Torney 07/21/17 11:23:30 AM
#2842   Institutional ownership news: SJSTOCKSHARK 07/21/17 10:38:46 AM
#2841   Just like was said in an earlier posting, iloveu2 07/20/17 11:57:17 PM
#2840   Thanks Brettj. I am not a patent expert SJSTOCKSHARK 07/20/17 09:30:51 PM
#2839   Some thoughts from a patent attorney I know Brettj 07/20/17 05:40:26 PM
#2838   They usually raise funds well before they would dmoffat 07/20/17 12:55:24 PM
#2837   Moffat I believe their present funds will last SJSTOCKSHARK 07/20/17 12:43:18 PM
#2836   That, and the need to raise funds soon. dmoffat 07/20/17 12:35:19 PM
#2835   I hope PN is working on the delisting. SJSTOCKSHARK 07/20/17 11:47:59 AM
#2834   GP, sorry move. SJSTOCKSHARK 07/19/17 09:29:05 PM
#2833   GP, Certainly PN deserves credit for handling the SJSTOCKSHARK 07/19/17 08:09:16 PM
#2832   And you are right this is powerful news Gpheart2016 07/19/17 06:35:28 PM
#2831   My only non-IRA trading account is a margin Gpheart2016 07/19/17 06:32:13 PM
#2830   Gp, I thought this WAS powerful news! It SJSTOCKSHARK 07/19/17 05:56:29 PM
#2829   Good questions. 1. Sellers on this news include short Gpheart2016 07/19/17 11:51:47 AM
#2828   GP, Three questions: SJSTOCKSHARK 07/19/17 11:41:58 AM
#2827   You are right, SJ. The shorts aren't going Gpheart2016 07/19/17 11:15:54 AM
#2826   GP, I am surprised we are not up more. SJSTOCKSHARK 07/19/17 10:55:43 AM
#2825   Big News! SJSTOCKSHARK 07/19/17 10:48:10 AM
#2824   I have had time to research our new SJSTOCKSHARK 07/17/17 02:35:34 PM
#2823   Here is the press release: SJSTOCKSHARK 07/17/17 10:44:53 AM
#2822   A positive move for BPTH. A new appointment Gpheart2016 07/17/17 10:26:34 AM
#2821   Moffat, A reverse split is never a positive SJSTOCKSHARK 07/14/17 03:06:06 PM
#2820   I am afraid his solution to that might dmoffat 07/14/17 02:35:47 PM
#2819   Moffat, They need to take action because of SJSTOCKSHARK 07/14/17 01:15:42 PM
#2818   There needs to be an update of current dmoffat 07/14/17 09:22:14 AM
#2817   GP, Wow! 1.3 million shares less short. Overall SJSTOCKSHARK 07/13/17 04:46:05 PM
#2816   I note that short interest dropped on 6/30/2017 Gpheart2016 07/13/17 02:15:54 PM
#2815   Thanks GP. SJSTOCKSHARK 07/13/17 10:08:37 AM
#2814   Thompson Reuters rates BPTH as "outperform" with a Gpheart2016 07/13/17 09:56:50 AM
#2813   Can anyone verify if that's true? dmoffat 07/12/17 08:00:01 PM
#2812   Pretty dead today..... hopefully some action tomorrow ShadeTrader 07/11/17 02:53:23 PM
#2811   A Stocktwits post says Thompson Reuters Verus upgraded SJSTOCKSHARK 07/11/17 10:25:42 AM
#2810   Here is an article explaining how "naked" shorting works. SJSTOCKSHARK 07/11/17 12:36:20 AM
#2809   I'm not 100% certain I understand how it BPTH2008 07/10/17 07:42:06 PM
#2808   I have not to my knowledge , but too simple 07/10/17 05:42:05 PM
PostSubject